Autoantibodies are already identified being biomarkers for future neuropsychiatric situations in SLE. A prospective study of 1047 SLE patients demonstrated that people who had proof of lupus anticoagulant (LA) experienced an increased future possibility of intracranial thrombosis and that Those people with anti-ribosomal P antibodies had an increas